Clover Health appoints Dr. Anna Loengard to Board of Directors

CLOVER HEALTH INVESTMENTS, CORP. /DE

Anna Loengard, M.D. appointed as Class I director effective November 28, 2022.
She will receive a pro-rata annual retainer and a pro-rated RSU award valued at $200,000.
Previously served as CMO of AccentCare, Caravan Health, and Queen's Healthcare System.
Her geriatric medicine and value-based care expertise supports Clover's in-home primary care strategy.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Anna Loengard, M.D.

Class I director

CLOV · CLOVER HEALTH INVESTMENTS, CORP. /DE

Effective: 2022-11-28
Filed: November 30, 2022, 6:59 PM ET

On November 28, 2022, the Board of Directors (the "Board") of Clover Health Investments, Corp. ("Clover" or the "Company") appointed Anna Loengard, M.D., to serve as a Class I director of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Anna Loengard, M.D. was appointed as Class I director at CLOVER HEALTH INVESTMENTS, CORP. /DE.

Action: appointed
Role: Class I director

Exact text from the filing

On November 28, 2022, the Board of Directors (the "Board") of Clover Health Investments, Corp. ("Clover" or the "Company") appointed Anna Loengard, M.D., to serve as a Class I director of the Board.

View on SEC.gov

CLOVER HEALTH INVESTMENTS, CORP. /DE filing history →

Source: SEC EDGAR

accession 0001801170-22-000090

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.